TAM June 2025 CME Posttest
Continuing Medical Education Posttest
The following Topics in Antiviral Medicine™ issue offers continuing medical education (CME) credit:
June 2025, Volume 33, Issue 3
Overview
- CME Credit Available: 8.0 AMA PRA Category 1 Credits™
- Release Date: June 30, 2025
- Expiration Date: June 30, 2026
To complete the activity, read each article and successfully complete the posttest and evaluation form, which will help us evaluate this activity and plan future activities. Your responses will not affect your CME credit.
Learning Objectives
On completion of this activity, which contains 5 articles, the learner will be better able to:
- Describe basic science research on HIV, including viral reservoirs and cure, and the latent reservoir
- Describe important data on metabolic complications in people with HIV, including cardiovascular disease, HIV and aging, and hepatic steatosis
- List the clinical manifestations of SARS-CoV-2, including acute COVID-19 disease and long COVID
- Describe the latest advances in the HIV care cascade, including advances in antiretroviral therapy
Assessment of Needs
The IAS–USA offers this state-of-the-art activity as part of a nationwide CME effort for physicians in the evolving challenges of managing HIV and other viral infections.
Intended Audience
This enduring material is designed for physicians who are actively involved in the medical care of people with HIV and other viral infections. This activity is also relevant for other practitioners, including nurse practitioners, nurses, physician assistants, pharmacists, and others.
CME Information
The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The IAS–USA designates this enduring material for a maximum of 8.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This CME activity is offered from June 30, 2025, to June 30, 2026. Participants who successfully complete the activity posttest and submit the evaluation and registration forms are eligible to receive CME credit. Physicians (MDs, DOs, and international equivalents) may receive CME credit for completing this activity. Other health care practitioners will receive a certificate of participation.
Disclosure of Financial Interests
It is the policy of the IAS–USA to ensure balance, independence, objectivity, and scientific rigor in all its educational activities.
In the interest of maintaining the independence of its continuing medical education (CME) activities, the International Antiviral Society–USA (IAS–USA) requires all persons with control of educational content (eg, faculty, Scientific Leadership Board, Governance Board, and program planner) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved and mitigated prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in IAS–USA CME activities.
The Accreditation Council for Continuing Medical Education (ACCME) defines ineligible companies as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.”
IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies for the presenter and planners/reviewers is below and in the slides prior to the presentation of educational content.
Contributors
Dr Antar reported no relevant financial relationships with ineligible companies. (Updated April 24, 2025)
Dr Brown reported serving as a consultant for EMD-Serono, Janssen, Merck & Co., Inc., Gilead Sciences, Inc, and ViiV Healthcare. (Updated May 19, 2025)
Dr Gunaratne reported no relevant financial relationships with ineligible companies. (Updated June 2, 2025)
Dr Peluso reported serving as a consultant for Gilead Sciences, AstraZeneca, BioVie, Apellis Pharmaceuticals, and BioNTech; and receiving research support from Aerium Therapeutics and Shionogi, outside the submitted work. (Updated May 19, 2025)
Dr Sarkar reported no relevant financial affiliations with ineligible companies. (Updated May 19, 2025)
Dr Stevenson reported serving as a consulting for and receiving grant support from Merck & Co., Inc. (Updated May 21, 2025)
Dr Taylor reported no relevant financial relationships with ineligible companies. (Updated June 2, 2025)
Dr Tieu reported receiving grant support awarded to her institution from GlaxoSmithKline. (Updated May 30, 2025)
Dr Wilkin reported serving as a consultant and receiving grant support awarded to his institution from GlaxoSmithKline, ViiV Healthcare, and Merck and Co., Inc. (Updated June 2, 2025)
Planners/Reviewers
Reviewer 1 reported consulting or advisor fees from Generate Biomedicines and Gilead Sciences, Inc. (Updated March 10, 2025)
Reviewer 2 reported no relevant financial relationships with ineligible companies. (Updated April 30, 2025)
Reviewer 3 reported no relevant financial relationships with ineligible companies. (Updated May 20, 2025)
Topics in Antiviral Medicine Editorial Board
Dr Richman reported consulting or advisor fees from Generate Biomedicines and Gilead Sciences, Inc. (Updated March 10, 2025)
Dr Benson reported receiving research grants from DNAe Group Holdings, Ltd, BioMerieux, and Gilead Sciences, Inc; serving as a consultant to NDA Partners LLC; serving as a scientific advisory board member for the INTREPID Alliance and Antiva, Inc., and as a member of a Data Safety Monitoring Board for ViiV/GlaxoSmithKline. (Updated April 30, 2025)
Dr Hirsch reported no relevant financial relationships with ineligeble companies. (Updated April 30, 2025)
Grant Support
This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from commercial companies. Per IAS–USA policy, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors:
PLATINUM SUPPORTERS
Gilead Sciences, Inc
Merck & Co, Inc
ViiV Healthcare
Contact Information
If you have any questions about this activity, please contact the IAS–USA:
Email: journal@iasusa.org
Mail: 131 Steuart St, Ste 500, San Francisco, CA 94105
Phone: (415) 544-9400
By clicking the link below, I acknowledge that I have read these instructions and understand them.
You must log in to take the activity.
You must be logged in to access this course.